EU approves smallpox vaccine for use against monkeypox

The European Commission has approved a smallpox vaccine for use against monkeypox after the World Health Organization declared monkeypox a global health emergency, the Danish drugmaker that developed the jab said on Monday

Updated - July 28, 2022 02:13 pm IST - Copenhagen

EU approves smallpox vaccine for use against monkeypox. A file photo of test tubes labeled “Monkeypox virus-positive and negative”.

EU approves smallpox vaccine for use against monkeypox. A file photo of test tubes labeled “Monkeypox virus-positive and negative”. | Photo Credit: Reuters

The European Commission has approved a smallpox vaccine for use against monkeypox after the World Health Organization declared monkeypox a global health emergency, the Danish drugmaker that developed the jab said on Monday.

“The European Commission has extended the marketing authorisation for the company’s smallpox vaccine, Imvanex, to include protection from monkeypox” in line with a recommendation by the EU’s medicines watchdog, Bavarian Nordic said in a statement.

“The approval... is valid in all European Union Member States as well as in Iceland, Liechtenstein, and Norway.”

Watch | What is the monkeypox virus?
A video explainer on the moneypox virus. | Video Credit: The Hindu

On Saturday, the WHO declared the monkeypox outbreak, which has affected nearly 16,000 people in 72 countries, to be a global health emergency – the highest alarm it can sound.

Imvanex has been approved in the EU since 2013 for the prevention of smallpox.

It was also considered a potential vaccine for monkeypox because of the similarity between the monkeypox virus and the smallpox virus.

Monkeypox is less dangerous and contagious than smallpox, which was eradicated in 1980.

The first symptoms of monkeypox are fever, headaches, muscle pain and back pain during the course of five days.

Rashes subsequently appear on the face, the palms of hands and soles of feet, followed by lesions, spots and finally scabs.

A surge in monkeypox infections has been reported since early May outside the West and Central African countries where the disease has long been endemic.

The EMA carries out a scientific assessment of drugs and gives a recommendation on whether any medicine should be marketed or not.

However, under EU law the EMA has no authority to actually permit marketing in the different EU countries. It is the European Commission which is the authorising body and takes a legally binding decision based on EMA’s recommendation.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.